CD47 Archives -

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion acquisition of

Gilead cleared to restart trials of CD47 drug magrolimab

https://pharmaphorum.com/news/gilead-cleared-to-restart-trials-of-cd47-drug-magrolimab/

Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a

Pfizer vaults into CD47 arena, buying Trillium for $2.3 billion

https://pharmaphorum.com/news/pfizer-vaults-into-cd47-arena-buying-trillium-for-2-3-billion/

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and

2nd Macrophage-directed Therapies Summit

https://pharmaphorum.com/events/2nd-macrophage-directed-therapies-summit/

Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations

ALX Oncology cancer drug claims two FDA fast-track reviews

https://pharmaphorum.com/news/alx-oncology-cancer-drug-claims-two-fda-fast-track-reviews/

CD47